AnaManzanoAparicioMD

Oncology • Houston, TX

Associate Professor, The University of Texas MD Anderson Cancer Center

Join to view full profile

Dr. Aparicio is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aparicio's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2000 - 2002
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1997 - 2000
Autonomous University of Madrid Class of 1995

Certifications & Licensure

CA State Medical License 1999 - Present
FL State Medical License 2021 - Present
TX State Medical License 2006 - 2025
OK State Medical License 2020 - 2021

Clinical Trials

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer Start of enrollment: 2006 May 01
Completed
Phase 2
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2016 May 18
Active, not recruiting
Phase 2
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Start of enrollment: 2017 Oct 03
Active, not recruiting
Phase 2
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Start of enrollment: 2020 Dec 29
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Start of enrollment: 2020 Aug 20
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) Start of enrollment: 2024 Feb 29
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Body composition in recurrent prostate cancer and the role of steroidogenic genotype.
Neha Venkatesh, Rebecca S Tidwell, Yao Yu, Ana Aparicio, Amado J Zurita
Endocrine-Related Cancer. 2024-12-01
A deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for accurate analysis of cell type ratios in complex tissue samples.
Shuai Guo, Xiaoqian Liu, Xuesen Cheng, Yujie Jiang, Shuangxi Ji
Genome Research. 2024-11-25
Polyploid cancer cells reveal signatures of chemotherapy resistance.
Michael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, Mohamed Kamal, Radu Cadaneanu
Oncogene. 2024-11-22

Lectures

Review EMT, Stemness and Tumor Plasticity in Aggressive Variant Neuroendocrine Prostate Cancers
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Paul Viscuse, MD, on Androgen-Indifferent Prostate CancersSeptember 8th, 2021
Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark FlemingJune 9th, 2021
Two-Time Cancer Survivor: MD Anderson Is Helping Me Beat the OddsDecember 1st, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member